[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
December 1, 2010

This Week in JAMA

JAMA. 2010;304(21):2323. doi:10.1001/jama.2010.1741

Some data suggest that omega-3 polyunsaturated fatty acids may be a safe and effective treatment option for patients with atrial fibrillation (AF). In a randomized, placebo-controlled, multicenter trial that enrolled patients with documented symptomatic paroxysmal or persistent AF and no structural heart disease, Kowey and colleagues assessed the efficacy and safety of pure prescription formulation high-dose (4 g/d) omega-3 fatty acids for the prevention of recurrent symptomatic AF. The authors report that compared with placebo, prescription omega-3 did not reduce the recurrence of symptomatic AF.

Active surveillance is an alternative to initial surgical or radiation treatment of patients with low-risk clinically localized prostate cancer, but long-term outcomes and the effect on quality of life have not been well characterized. Hayes and colleagues Article report results of a decision analysis that examined the quality-adjusted life expectancy of active surveillance compared with initial treatment (defined as radical prostatectomy, radiation therapy, or brachytherapy) in hypothetical cohorts of 65-year-old men with newly diagnosed and clinically localized low-risk prostate cancer. The authors found that active surveillance was a reasonable approach; however, the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment. In an editorial, Thompson and Klotz Article discuss active surveillance as an option for men with low-risk prostate tumors.